About this episode
This episode features expert interviews discussing key findings from the 2026 ASCO Annual Meeting.
This episode of VJOncology podcasts brings together five expert interviews from the 2026 ASCO Annual Meeting in Chicago, covering practice-changing data across prostate cancer, sarcoma, lung cancer, colorectal cancer, and triple-negative breast cancer. Highlights include final analysis results from the PROTEUS trial supporting perioperative apalutamide plus ADT as a new standard of care, SARC041 data on abemaciclib in dedifferentiated liposarcoma, lung cancer updates from the DeLLphi-304, LIBRETTO-432, and ALCHEMIST trials, BREAKWATER Cohort 3 data establishing encorafenib plus cetuximab with FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer, and PFS2 analyses from ASCENT-04 reinforcing sacituzumab govitecan plus pembrolizumab in metastatic triple-negative breast cancer.
Topics covered
- oncology
- cancer research
- ASCO highlights
- prostate cancer
- lung cancer
- colorectal cancer
- triple-negative breast cancer
Keywords
- ASCO 2026
- cancer treatment
- clinical trials
- oncology updates
- sarcoma
- metastatic cancer
- PFS2 analyses
Mentioned in this episode
Organizations: ASCO
Products: apalutamide, ADT, abemaciclib, encorafenib, cetuximab, FOLFIRI, sacituzumab govitecan, pembrolizumab
Places: Chicago
More episodes of VJOncology Podcast
- Gastrointestinal cancer updates at ASCO 2026: RASolute 302, EMERALD-3, and more · June 12, 2026 · 16 min
- iwCAR-T 2026: CARs targeting cell surface proteins · May 15, 2026 · 17 min
- Bladder Cancer Awareness Month: subtypes, diagnostics & breakthroughs · May 8, 2026 · 16 min
- Oncology highlights from AACR 2026 · May 1, 2026 · 18 min
- Beyond EGFR: navigating molecular targets and emerging therapies in advanced NSCLC · April 30, 2026 · 17 min
- Head and neck cancer awareness month: key trials and evolving treatment strategies · April 17, 2026 · 14 min
Explore listener stats, chart rankings, contacts and more on the VJOncology Podcast podcast page.